➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
Colorcon
Johnson and Johnson
Dow

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXEMESTANE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Exemestane

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002777 Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1996-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status UNICANCER Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exemestane

Condition Name

Condition Name for Exemestane
Intervention Trials
Breast Cancer 92
Breast Neoplasms 23
Metastatic Breast Cancer 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exemestane
Intervention Trials
Breast Neoplasms 179
Neoplasms 9
Breast Neoplasms, Male 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exemestane

Trials by Country

Trials by Country for Exemestane
Location Trials
United States 792
Italy 95
Canada 93
Japan 60
United Kingdom 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exemestane
Location Trials
California 34
Florida 33
Texas 33
New York 31
Washington 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exemestane

Clinical Trial Phase

Clinical Trial Phase for Exemestane
Clinical Trial Phase Trials
Phase 4 9
Phase 3 48
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exemestane
Clinical Trial Phase Trials
Recruiting 56
Completed 54
Active, not recruiting 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exemestane

Sponsor Name

Sponsor Name for Exemestane
Sponsor Trials
National Cancer Institute (NCI) 31
Pfizer 31
Novartis Pharmaceuticals 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exemestane
Sponsor Trials
Other 182
Industry 114
NIH 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Merck
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.